Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Patel, Vanlata ^a   Adya, Raghu ^a   Chen, Jing ^a   Ramanjaneya, Manjunath ^a   Bari, Muhammad F ^a,b   Bhudia, Sunil K ^c   Hillhouse, Edward W ^d   Tan, Bee K ^a   Randeva, Harpal S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Dow International Medical College   (Pakistan)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^d HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

BETA KLOTHO PROTEIN; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 21 RECEPTOR 1; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KLOTHO PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTECTIVE AGENT; PROTEIN KINASE B; RETINOID RELATED ORPHAN RECEPTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HYPOXIA; MALE; NONHUMAN; OBESITY; PARACRINE SIGNALING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CONFOCAL MICROSCOPY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEART; HEART MUSCLE; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HEART; HUMANS; IN VITRO TECHNIQUES; MALE; MICROSCOPY, CONFOCAL; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 1; OBESITY; PHOSPHATIDYLINOSITOL 3-KINASE; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84895499713     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087102     Document Type: Article

References (46)

1. Braunwald E (1997) Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337: 1360-1369.
2. Shah PK, Forrester JS (1991) Pathophysiology of acute coronary syndromes. Am J Cardiol 68: 16C-23C.
3. Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, et al. (2012) The innate immune response in reperfused myocardium. Cardiovasc Res 94: 276-283.
4. Liu SQ, Tefft BJ, Liu C, Zhang B, Wu YH. (2011) Regulation of hepatic cell mobilization in experimental myocardial ischemia. Cell Mol Bioeng 4: 693-707, 2011.
5. Valina C, Pinkernell K, Song YH, Bai X, Sadat S, et al. (2007) Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J 28: 2667-2677. (Pubitemid 350071533)
6. Liu SQ, Tefft BJ, Roberts DT, Zhang LQ, Ren Y, et al. (2012) Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. Am J Physiol Heart Circ Physiol 303: H1446-1458.
7. Liu SQ, Wu YH (2010) Liver cell-mediated alleviation of acute ischemic myocardial injury. Front Biosci (Elite Ed) 2: 711-724.
8. Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206. (Pubitemid 30349198)
9. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
10. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. The Journal of clinical investigation 115: 1627-1635. (Pubitemid 40814671)
11. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, et al. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71: 369-375.
12. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, et al. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59: 2781-2789.
13. Tan BK, Hallschmid M, Adya R, Kern W, Lehnert H, et al. (2011) Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60: 2758-2762.
14. Li H, Bao Y, Xu A, Pan X, Lu J, et al. (2009) Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma- glutamyltransferase but not insulin sensitivity in Chinese subjects. The Journal of clinical endocrinology and metabolism 94: 2151-2156.
15. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, et al. (2007) The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 34: 621-628. (Pubitemid 46483091)
16. Uebanso T, Taketani Y, Yamamoto H, Amo K, Tanaka S, et al. (2012) Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. J Nutr Biochem 23: 785-790.
17. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM, (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151. (Pubitemid 40105106)
18. Sharma A, Singh M (2000) Effect of ethylisopropyl amiloride, a Na+ - H+ exchange inhibitor, on cardioprotective effect of ischaemic and angiotensin preconditioning. Molecular and cellular biochemistry 214: 31-38. (Pubitemid 32010324)
19. Rodrigo GC, Chapman RA (1991) The calcium paradox in isolated guinea-pig ventricular myocytes: effects of membrane potential and intracellular sodium. The Journal of physiology 434: 627-645.
20. Mitra R, Morad M (1985) A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. The American journal of physiology 249:H1056-1060. (Pubitemid 16197350)
21. Adya R, Tan BK, Punn A, Chen J, Randeva HS (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovascular research 78: 356-365. (Pubitemid 351556097)
22. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, et al. (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. PNAS 104: 7432-7437. (Pubitemid 47185923)
23. Matsui T, Li L, del Monte F, Fukui Y, Franke TF, et al. (1999) Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100: 2373-2379.
24. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, et al. (1998) Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 38: 116-124. (Pubitemid 28275621)
25. Wang Y, Solt LA, Burris TP (2010) Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor alpha. J Biol Chem 285: 15668-15673.
26. Lionetti V, Bianchi G, Recchia FA, Ventura C (2010) Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure. Heart Fail Rev 15: 531-542.
27. Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R (2012) The cardioprotective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2: 253-266.
28. Doroudgar S, Glembotski CC (2013) New concepts of endoplasmic reticulum function in the heart: programmed to conserve. J Mol Cell Cardiol 55: 85-91.
29. Attie AD, Scherer PE (2009) Adipocyte metabolism and obesity. J Lipid Res 50 Suppl: S395-399.
30. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, et al. (2013) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4: 2019.
31. Hausenloy DJ, Mocanu MM, Yellon DM (2004) Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 63: 305-312. (Pubitemid 38900844)
32. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328.
33. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, et al. (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366: 1640-1649. (Pubitemid 41552419)
34. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, et al. (2002) Obesity and the risk of heart failure. N Engl J Med 347: 305-313. (Pubitemid 34815352)
35. Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, et al. (2006) Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med 7: 7-11.
36. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, et al. (2006) Association of body weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368: 666-678. (Pubitemid 44223694)
37. Thim T, Bentzon JF, Kristiansen SB, Simonsen U, Andersen HL, et al. (2006) Size of myocardial infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome. Clin Sci (Lond) 110: 665-671. (Pubitemid 43844736)
38. Yie J, Wang W, Deng L, Tam LT, Stevens J, et al. (2012) Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol Drug Des 79: 398-410.
39. Jiao H, Arner P, Dickson SL, Vidal H, Mejhert N, et al. (2011) Genetic association and gene expression analysis identify FGFR1 as a new susceptibility gene for human obesity. J Clin Endocrinol Metab 96: E962-966.
40. Yie J, Hecht R, Patel J, Stevens J, Wang W, et al. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583: 19-24.
41. Yang C, Jin C, Li X, Wang F, McKeehan WL, et al. (2012) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7: e33870.
42. Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, et al. (2012) TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153: 4238-4245.
43. Lopaschuk GD (1997) Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Am J Cardiol 80: 11A-16A.
44. Morabito D, Montessuit C, Rosenblatt-Velin N, Lerch R, Vallotton MB, et al. (2002) Impaired glucose metabolism in the heart of obese Zucker rats after treatment with phorbol ester. Int J Obes Relat Metab Disord 26: 327-334. (Pubitemid 34226157)
45. Bertinchant JP, Polge A, Robert E, Sabbah N, Fabbro-Peray P, et al. (1999) Time-course of cardiac troponin I release from isolated perfused rat hearts during hypoxia/reoxygenation and ischemia/reperfusion. Clin Chim Acta 283: 43-56. (Pubitemid 29324952)
46. Mair J (1999) Tissue release of cardiac markers: from physiology to clinical applications. Clin Chem Lab Med 37: 1077-1084.